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SmokingAbstract Selenium is an essential trace element with potent antioxidant activity. It is a natural
health product widely used in the treatment and prevention of lung cancers.
Aim of work: To assess the selenium levels in the epithelial lining ﬂuid, broncho-alveolar lavage
and in the serum of non small cell lung cancer patients in comparison with a healthy smoker group
and a healthy non smoker group as the control group.
Subjects and methods: Fifty candidates participated in this work. They were classiﬁed into; 20
patients with non small cell lung cancer, 15 healthy smoker subjects and 15 healthy non smoker sub-
jects as the control group.
Results: The serum level of selenium was highly signiﬁcantly lower in non small cell lung cancer
patients compared with healthy smokers and healthy non smoker individuals (48.5 ± 9.2, 72 ± 14
and 87 ± 11.3 respectively, P< 0.001). The BAL level of selenium was highly signiﬁcantly lower in
non small cell lung cancer patients compared with healthy smokers and healthy non smoker indi-
viduals (1.95 ± 0.42, 2.02 ± 0.3 and 2.69 ± 0.2 respectively, P< 0.001). Also, the mean concen-
tration of selenium in the epithelial lining ﬂuid was highly signiﬁcantly lower in non small cell
lung cancer patients compared with healthy smokers and healthy non smoker individuals
(230 ± 16.4, 289 ± 11.2 and 375.06 ± 15 respectively, P< 0.001).
Conclusion: Lower levels of selenium in the serum, BAL and ELF were associated with non
small cell lung cancer and to a lesser extent with smokers compared with non smoker healthy indi-
viduals.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Lung cancer is the most common cause of cancer death in the
world, and an estimated 1.04 million new cases occur world-
wide each year [1]. Smoking is clearly the most common cause
of this disease, but factors such as occupational exposures,
1 An informed consent was obtained from each subject.
1020 G. Elassal et al.household radon, and certain dietary constituents may also
have important impacts on lung cancer risks [2].
Given this, a large number of epidemiologic studies have
been undertaken to identify potential risk factors for cancer,
among which the association with trace elements has received
considerable attention [3].
Reduction of oxygen (occurring in all aerobic organisms),
results in the formation of reactive oxygen species (ROS), such
as hydrogen peroxide, hydroxyl radicals and superoxide. These
are directly responsible for the detrimental effects of ‘‘oxida-
tive stress’’ which is a consequence of a disturbance in the bal-
ance between reactive oxygen species (ROS) and endogenous
antioxidant defenses, leading to oxidation of lipids, proteins,
and DNA in ways that impair cellular functions [4].
Generation of reactive oxygen species is linked to a variety
of environmental factors like ultraviolet radiation, cigarette
smoking, and alcohol consumption. To counteract the effects
of ROS in vivo, there are a number of distinct antioxidant
mechanisms in place within the cell, such as superoxide dismu-
tase, catalase, ascorbic acid, glutathione, and selenium [5].
Selenium is an essential trace element with potent antioxi-
dant activity mediated through its ability to increase the activ-
ity of the glutathione peroxidase enzymes. Selenium has long
been regarded as possessing anticancer effects based on early
experiments from the early 1900s that showed regression of
carcinoma and sarcoma in vivo [6]. It takes part in a system
converting aggressive oxidation products, intracellular free
radicals, into less reactive or neutral components [7].
This work aims to assess the selenium levels in the epithelial
lining ﬂuid, broncho-alveolar lavage and in the serum of non
small cell lung cancer patients in comparison with a healthy
smoker group and a healthy non smoker group as the control
group.
Subjects and methods
This study was conducted at the Chest Department, Ain
Shams University hospitals from June 2013 to January 2014.
Fifty candidates participated in this work. They were classiﬁed
into; 20 patients presented as suspicious cases of lung cancer
and proved by investigations to have non small cell lung can-
cer, 15 healthy smoker subjects and 15 healthy non smoker
subjects as the control group.
All candidates were subjected to the following:
– Full history taking.
– Thorough clinical examination.
– Routine laboratory investigations.
– CXR and CT chest.
Biological samples
Blood sample collection and handling
Venous blood (5 mL) was withdrawn and collected in plain
vacutainers, the separated sera were divided into two aliquots.
The ﬁrst aliquot was used for the assay of serum urea. The sec-
ond aliquot was collected in plain vacutainers and stored at
20 C for selenium determination with Inductively Coupled
Plasma (ICP) spectroscopy (Perkin Elmer Optima 4300, DV,
USA).Bronchoalveolar lavage ﬂuid (BAL)
Atropine 1 mg was injected intramuscularly 60 min before
bronchoscopy was done, and local anesthesia of the upper air-
ways was given using lignocaine spray 10%, then vocal cords,
trachea, main carina, and the two main bronchi were anesthe-
tized using one milliliter aliquots of lignocaine 2% solution.
The ﬂexible bronchoscope was wedged in a sub segment of
the middle lobe, and ﬁve serial infusions and aspirations were
performed, each of 20 mL sterile saline (0.9% sodium
chloride).
The ﬂuid recovered was collected in polyethylene tubes kept
on ice. The recovered ﬂuid was measured and ﬁltered through
two single layers of sterile gauze and centrifuged at 500 rpm
for 10 min at 4 C in order to separate the cellular constituents.
Epithelial lining ﬂuid volume (ELF)
The volume of ELF was calculated by the following formula:
ELF volume (ml) = BAL urea/sera urea · recovered BAL
volume (ml) [8]. Concentrations of urea in BALF and serum
were determined by a BM- Hitachi 911 automated analyzer
with the original kits of Boehringer-Mannheim based on the
urease method [9]. The dilution factor obtained was used to
calculate selenium concentrations in ELF.
The healthy smoker and non smoker groups were undergo-
ing ﬁber-optic bronchoscopy for foreign body extraction.1
Statistical analysis
Data were collected, tabulated and statistically analyzed. All
statistical procedures were carried out using SPSS version 15
for Windows (SPSS Inc, Chicago, IL, USA).
Results
The current study was conducted on 50 candidates. They were
classiﬁed into; 20 patients with non small cell lung cancer, 15
healthy smoker subjects and 15 healthy non smoker subjects
as the control group.
The serum level of selenium was highly signiﬁcantly lower
in non small cell lung cancer patients compared with healthy
smokers and healthy non smoker individuals (48.5 ± 9.2,
72 ± 14 and 87 ± 11.3 respectively, P< 0.001) (Table 1 and
Fig. 3).
The BAL level of selenium was highly signiﬁcantly lower in
non small cell lung cancer patients compared with healthy
smokers and healthy non smoker individuals (1.95 ± 0.42,
2.02 ± 0.3 and 2.69 ± 0.2 respectively, P< 0.001) (Table 1
and Fig. 2).
Also, the mean concentration of selenium in the epithelial
lining ﬂuid was highly signiﬁcantly lower in non small cell lung
cancer patients compared with healthy smokers and healthy
non smoker individuals (230 ± 16.4, 289 ± 11.2 and
375.06 ± 15 respectively, P< 0.001) (Table 1 and Fig. 1).
On comparing the studied groups together, the healthy
smoker group showed a signiﬁcantly lower levels of selenium
in the serum, BAL and ELF (72 ± 14, 2.02 ± 0.3,
289 ± 11.2 respectively) compared with these levels in the
healthy non smoker group (87 ± 11.3, 2.69 ± 0.2 and
375.06 ± 15 respectively).





Min 47 1.7 320
Max 122 4.2 420
Mean ± SD 87 ± 11.3 2.69 ± 0.2 375.06 ± 15
Healthy smokers
Min 45 1.23 201
Max 105 2.2 320
Mean ± SD 72 ± 14 2.02 ± 0.3 289 ± 11.2
Change% 82.7 75.09 77.1
P< 0.001 0.001 0.001
Cancer patients
Min 35 1.24 190
Max 52 2.3 260
Mean ± SD 48.5 ± 9.2 1.95 ± 0.42 230 ± 16.4
Change% 48.5 72.49 61.3
P< 0.001 0.001 0.001
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Figure 1 The mean level of ELF selenium in different studied
groups.
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Figure 2 The mean selenium level in the BAL in different
studied groups.
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Figure 3 The mean level of serum selenium in different studied
groups.
Signiﬁcance of selenium levels in non-small cell lung cancer patients 1021The non small cell lung cancer patients showed a signiﬁ-
cantly lower levels of selenium in the serum, BAL and ELF
(48.5 ± 9.2, 1.95 ± 0.42 and 230 ± 16.4 respectively) com-
pared with these levels in the smoker and non smoker healthy
groups (Fig. 4).
All groups were matched together as regards age and sex
with no statistical signiﬁcant difference between them.
Discussion
In the current study we aimed to assess the selenium levels in
the epithelial lining ﬂuid, broncho-alveolar lavage and in the
serum of non small cell lung cancer patients in comparisonwith a healthy smoker group and a healthy non smoker group
as the control group.
In the present study the serum level of selenium was signif-
icantly lower in the non small cell lung cancer group in com-
parison with the smoker healthy group and the non smoker
healthy group (48.5 ± 9.2 lg/ml, 72 ± 14 lg/ml and
87 ± 11.3 lg/ml respectively, P< 0.001) and the serum level
of selenium was lower in the healthy smoker group than in
the healthy non smoker group.
This coincides with another research [10] that studied the
selenium concentration in whole blood and plasma, as well
as in cancerous and tumor-free lung tissue of lung cancer
patients. Blood samples were taken from 84 cancer patients
and 61 healthy controls. Normal and neoplastic lung tissues
Change % of selenium level in cancer lung and smoker












Figure 4 Comparison between the studied groups as regards
selenium levels in the serum, BAL, and ELF.
1022 G. Elassal et al.were obtained from 57 patients at the time of surgery. Sele-
nium concentrations in whole blood and plasma were lower
by 23% (P< 0.001) in patients compared with controls. On
the other hand, the tumor selenium level was higher by
66.6% (P< 0.0001) than that in adjacent tumor-free tissue.
In the whole blood and plasma of cancer patients signiﬁcantly
lower selenium concentrations were found in smokers than in
non smokers. Signiﬁcantly lower selenium concentrations were
also found among cancer patients who were smokers com-
pared with controls. They stated that the cause of increased
selenium in the malignant part of the lung is not understood
and requires further studies.
This also coincides with a case–control study conducted in
a region of north western Poland, on 86 cases of lung cancer,
87 cases of laryngeal cancer and an equal number of healthy
controls and studied the serum level of selenium. They found
that among lung cancer cases, the mean selenium level was
63.2 lg/l, compared with a mean level of 74.7 lg/l in their
matched controls (P< 0.0001) [11].
It also agrees with another study which suggested that low
selenium status may be associated with increased risk of lung
cancer [12].
In another work they stated that individuals with a low
serum selenium concentration had an elevated risk of lung can-
cer and it was pronounced among smokers [13].
However this disagrees with other co-authors who found no
signiﬁcant overall associations between prospectively collected
serum levels of selenium and lung cancer [14].
Many studies assessed selenium levels in lung cancer, they
used serum, whole blood, selenium proteins levels and even
toenail level of selenium. However, we found that no available
studies used bronchoalveolar lavage or epithelial lining ﬂuid in
measuring selenium levels in lung cancer.
In the current study the selenium levels in the BAL were
lower in the smoker healthy group compared with the non
smoker healthy group and it was signiﬁcantly lower in the can-
cerous group compared with the other two groups. The sele-
nium levels were 1.95 ± 0.42 lg/ml, 2.02 ± 0.3 lg/ml and
2.69 ± 0.2 lg/ml in the cancerous group, smoker group and
non smoker group respectively (P< 0.001).
Also, in measuring the selenium levels in ELF they were sig-
niﬁcantly lower in cancerous patients in comparison with smo-
ker and non smoker groups (230 ± 16.4, 289 ± 11.2 and375.06 ± 15 respectively, P< 0.001) and the selenium levels
were lower in the smoker group than in the non smoker group.
An interesting ﬁnding was that values of selenium in serum,
BAL, and ELF were lower among smokers compared with val-
ues observed among controls who had never smoked. This
could be explained by the fact that smoking is associated with
excessive burden of oxidants or free radicals, either inhaled or
generated by inﬂammatory cells, the decrease seen in the
endogenous antioxidant selenium might have resulted from a
compensatory response to the chronic exposure to cigarette
smoke free radicals.
In the present study, selenium levels in blood, BALF, and
ELF decreased with lung cancer, a condition that might be
due to exhaustion of antioxidant mechanisms during chronic
inﬂammation and hyperproliferative process (depletion of
antioxidant stores) adding further support for the involvement
of oxidative stress in cancer process.
This coincides with Zachara et al. [10], who found that sele-
nium and glutathione levels in serum, whole blood and cancer
free tissue were lower than those in healthy and cancerous tis-
sues. They assumed that increased activity of glutathione in
cancerous lung tissue may reﬂect increased accumulation of
active oxygen species and probably organic hydroperoxides
in the tissue. The mechanism by which selenium is accumu-
lated in the cancerous part of the lung is not known. Regard-
less of the mechanism, the accumulated element stimulates the
synthesis of glutathione which is necessary to destroy active
oxygen species and hydroperoxides.
In another study, they mentioned that patients with lung
cancer have marked modiﬁcations in their ELF antioxidant
defences in comparison with those of smokers. It is difﬁcult
to distinguish whether changed antioxidant status is a primary
disturbance involved in the cancer process or whether it is a
consequence of the neoplastic changes in malignancy [15].
Moreover, many studies suggested that selenium may be
effective for lung cancer prevention among individuals with
lower selenium status [16,17].
In agreement with this selenium has been suggested to pre-
vent tumor development by multiple potential mechanisms
that impact distinct stages of carcinogenesis. In antioxidant
systems, selenium can participate by incorporation as seleno-
cysteine into more than 25 selenoproteins, such as glutathione
peroxidase and thioredoxin reductase. Many studies have sug-
gested that selenium may also play a role in minimizing DNA
damage as well as augmenting DNA repair capacity [18].
However, other authors concluded that there appears to be
a differential chemopreventive effect dependent on baseline
selenium status, such that selenium supplementation may
reduce the risk of lung cancers in populations with lower base-
line selenium status but increase the risk of lung cancers in
those with higher selenium [16].
Also, in another study they stated that selenium supplemen-
tation did not signiﬁcantly decrease lung cancer incidence in
the full population, but a signiﬁcant decrease among individu-
als with low baseline selenium concentrations was observed
[19].
Conclusion
Lower levels of selenium in the serum, BAL and ELF were
associated with non small cell lung cancer and to a lesser extent
Signiﬁcance of selenium levels in non-small cell lung cancer patients 1023with smokers compared with non smoker healthy individuals.
Oxidative stress and antioxidant role of selenium could be a
suggested explanation. However, the deﬁnite role of selenium
and its mechanism in the cancer process are not clear yet. Also,
its preventive activity against cancer is controversial. On the
other hand, studying the role of selenium and other trace ele-
ments and antioxidants in the mechanism of malignancy could
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